HAMP and anemia (phenotype): When hepcidin is made to increase five-fold for a period of 365 days, the model predicts a loss of plasma iron accompanied by decreasing levels of iron in bone marrow, red blood cells (causing the anemia) and the rest of the body, while there is an increase in duodenal iron concentration (due to the inhibition of duodenal ferroportin) and transient increases in spleen and liver iron.